Ibutamoren (MK-677)
Ibutamoren Mesylate • Also called MK-677, MK 677, Ibutamoren
Ibutamoren, often referred to as MK-677, remains commercially visible online but sits in FDA's restricted compounding bucket.
Current status
Restricted
Growth-hormone- and appetite-related interest, with current federal compounding constraints still in play.
FDA category
Category 2
Can pharmacies compound this?
No
Reclassification expected?
Unclear
It remains popular in performance markets, but there is no comparably strong FDA review signal pointing toward near-term easing.
Primary Use
Growth-hormone- and appetite-related interest
Also searched as
MK-677, MK 677, Ibutamoren
Regulatory Timeline
Feb 27, 2026
Political pressure and market expectations increased around a future peptide reclassification review.
Sep 27, 2024
Current status signal recorded: Listed by FDA in Category 2 for significant safety concerns..
Mar 15, 2023
FDA peptide compounding scrutiny intensified across 503A and 503B channels.
Get notified...
Get notified when Ibutamoren (MK-677) status changes
State-specific notes
Texas
Performance-oriented demand does not create a compliant pharmacy pathway.